文献速递骨质疏松与代谢性骨病小儿骨科

儿童期佩吉特病对帕米膦酸获得性耐药后唑来膦酸治疗有效

Acquired resistance to pamidronate treated effectively with zoledronate in juvenile Paget's disease.
PubMed 文献 · Osteoporos Int · 2018-03-03

一例9月龄男婴因骨痛、畸形和高碱性磷酸酶确诊儿童期佩吉特病,基因分析示TNFRSF11B基因纯合大缺失。静脉帕米膦酸治疗初期临床改善,但2年后疗效减退、骨折和骨痛复发,提示耐药;换用唑来膦酸后影像学和碱性磷酸酶显著改善,首剂出现需静脉补钙的严重低钙血症,后续未再复发。

要点

  • 婴儿期起病的儿童期佩吉特病,静脉帕米膦酸可减轻骨痛、改善骨畸形和运动发育。
  • 帕米膦酸疗效可能短暂,出现骨折、骨痛复发和高碱性磷酸酶提示耐药。
  • 帕米膦酸耐药后换用唑来膦酸可获长期临床和生化改善,首剂需警惕严重低钙血症。

核心结论

  • 静脉帕米膦酸治疗对婴儿期起病的儿童期佩吉特病可有效减轻骨痛、改善骨畸形和运动发育,但该效应可能是短暂的。
  • 对帕米膦酸耐药时,换用另一种双膦酸盐如唑来膦酸可能作为替代治疗提供长期临床和生化改善。

研究设计与样本

  • 本文为单例病例报告,对象为1例9月龄男婴,因骨痛和畸形伴极高碱性磷酸酶水平,经影像学表现诊断为儿童期佩吉特病。
  • 基因分析显示TNFRSF11B基因(编码骨保护素)存在纯合大缺失。

主要发现

  • 静脉帕米膦酸治疗初期观察到临床改善,但2年后药物效果随时间减退,按每公斤体重计算的年剂量增加。
  • 尽管增加剂量,仍出现骨折、骨痛复发伴高碱性磷酸酶水平,提示对帕米膦酸耐药。
  • 换用唑来膦酸后,影像学骨表现和碱性磷酸酶水平显著改善。
  • 唑来膦酸首剂出现需静脉补钙治疗的严重低钙血症,此后未再复发。

临床怎么用

  • 作者认为,对帕米膦酸耐药的儿童期佩吉特病,换用唑来膦酸可能提供长期临床和生化改善,可作为替代治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Juvenile Paget's disease (JPD) is a rare autosomal recessive osteopathy. There is still a question about the most effective treatment modality in long-term prognosis. A 9-month-old boy who suffered from bone pain and deformities with a very high alkaline phosphatase level was diagnosed as JPD by radiographic findings. Genetic analysis showed a homozygous large deletion in TNFRSF11B gene encoding osteoprotegerin. Clinical improvement was observed with intravenous pamidronate therapy. However, the effect of drug reduced in time so the annual dose per kilogram body weight was increased after 2 years. Despite this increment, bone fractures developed and bone pain recurred with high-ALP levels, which suggested resistance to pamidronate. Switching to zoledronate resulted a significant improvement in bone findings radiographically and ALP level. Severe hypocalcemia requiring intravenous calcium treatment complicated the first dose of zoledronate, but not recurred thereafter. Intravenous pamidronate therapy is effective in reducing bone pain, improving bone deformities and motor development in infantile onset JPD. However, this effect can be transient. Switching to another bisphosphonate like zoledronate may provide long-term clinical and biochemical improvement as an alternative treatment in case of resistance to pamidronate therapy.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Gonc EN, Ozon A, Buyukyilmaz G, et al. Acquired resistance to pamidronate treated effectively with zoledronate in juvenile Paget's disease. Osteoporos Int. 2018. PMID: 29502293. doi:10.1007/s00198-018-4443-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。